Abstract
The glycoprotein CD36, also known as glycoprotein IIIb/IV or FAT, is expressed on the surface of platelets, monocytes, microvascular endothelial cells, smooth muscle cells, cardiomyocytes and other cells of the cardiovascular system. In spite of its abundant presence, CD36 has remained for long a mysterious protein with a poorly understood role. In this paper, we review how CD36 can affect cellular responses by interaction with a variety of ligands, in particular thrombospondin-1, oxidized lipoproteins and fatty acids. Furthermore, given the structure of CD36 with two transmembrane domains and short cytoplasmic tails, we consider how this receptor can induce intracellular signaling, likely in junction with other cellular receptors or associated proteins in the membrane. Current literature points to activation of Src-family and mitogen-activated protein kinases, as well as to activation of the NFκB and Rho pathways. The new insights make CD36 attractive as a therapeutic target to suppress platelet and monocyte/macrophage function and thereby atherothrombosis.
Keywords: Atherothrombosis, monocytes, lipoproteins, macrophages, thrombospondin, CD36, glycoprotein, cardiomyocytes, thrombospondin-1, Src-family, mitogen-activated protein kinases, hrombospondin-1, oxidized phospholipids, scavenger receptor B1, CD36 gene, C-terminus, Drosophila, ABC transporter, Streptococcus, cysteine residues, disulfide bonds, Plasmodium falciparum, phosphorylation site, Collagen, fibroblasts, anti-CD36 antibodies, Scavenger, clathrin-mediated endocytosis, Adipocytes, myocytes, hexarelin, Syk kinases
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: CD36 as a Multiple-Ligand Signaling Receptor in Atherothrombosis
Volume: 9 Issue: 1
Author(s): R. Nergiz-Unal, T. Rademakers, J. M.E.M. Cosemans and J. W.M. Heemskerk
Affiliation:
Keywords: Atherothrombosis, monocytes, lipoproteins, macrophages, thrombospondin, CD36, glycoprotein, cardiomyocytes, thrombospondin-1, Src-family, mitogen-activated protein kinases, hrombospondin-1, oxidized phospholipids, scavenger receptor B1, CD36 gene, C-terminus, Drosophila, ABC transporter, Streptococcus, cysteine residues, disulfide bonds, Plasmodium falciparum, phosphorylation site, Collagen, fibroblasts, anti-CD36 antibodies, Scavenger, clathrin-mediated endocytosis, Adipocytes, myocytes, hexarelin, Syk kinases
Abstract: The glycoprotein CD36, also known as glycoprotein IIIb/IV or FAT, is expressed on the surface of platelets, monocytes, microvascular endothelial cells, smooth muscle cells, cardiomyocytes and other cells of the cardiovascular system. In spite of its abundant presence, CD36 has remained for long a mysterious protein with a poorly understood role. In this paper, we review how CD36 can affect cellular responses by interaction with a variety of ligands, in particular thrombospondin-1, oxidized lipoproteins and fatty acids. Furthermore, given the structure of CD36 with two transmembrane domains and short cytoplasmic tails, we consider how this receptor can induce intracellular signaling, likely in junction with other cellular receptors or associated proteins in the membrane. Current literature points to activation of Src-family and mitogen-activated protein kinases, as well as to activation of the NFκB and Rho pathways. The new insights make CD36 attractive as a therapeutic target to suppress platelet and monocyte/macrophage function and thereby atherothrombosis.
Export Options
About this article
Cite this article as:
Nergiz-Unal R., Rademakers T., M.E.M. Cosemans J. and W.M. Heemskerk J., CD36 as a Multiple-Ligand Signaling Receptor in Atherothrombosis, Cardiovascular & Hematological Agents in Medicinal Chemistry 2011; 9 (1) . https://dx.doi.org/10.2174/187152511794182855
DOI https://dx.doi.org/10.2174/187152511794182855 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Revised Genetic Classification of Limb Girdle Muscular Dystrophies
Current Molecular Medicine Use of BNP and CRP as Biomarkers in Assessing Cardiovascular Disease:Diagnosis Versus Risk
Current Vascular Pharmacology Sepsis Pathophysiology and Anesthetic Consideration
Cardiovascular & Hematological Disorders-Drug Targets The Role of microRNAs in Cardiovascular Disease
Current Medicinal Chemistry Gene Patents in the Primary Prevention of Vascular Diseases
Recent Patents on DNA & Gene Sequences Roles of p38-MAPK in Insulin Resistant Heart: Evidence from Bench to Future Bedside Application
Current Pharmaceutical Design Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design The Fluctuations of Melatonin and Copeptin Levels in Blood Serum During Surgical Stress Regarding the Pediatric Population
Current Pediatric Reviews Changes in the Expression of the Alzheimers Disease-Associated Presenilin Gene in Drosophila Heart Leads to Cardiac Dysfunction
Current Alzheimer Research Human Tissue Kallikrein: A New Bullet for the Treatment of Ischemia
Current Pharmaceutical Design State of the Heart: CMR in Coronary Artery Disease
Current Medical Imaging Editorial [Hot Topic: Why Apoptosis in Pediatric Disorders?]
Current Pediatric Reviews Atrial Conduction Disorders
Current Cardiology Reviews COVID-19 Effects on Geriatric Population and Failures of Aminoquinoline Therapy: Compilation of Studies from EU, USA, and China; Safety and Efficacy of Vaccines in the Prevention and Treatment of COVID-19
Current Medicinal Chemistry Targeted Gene Deletion of Prolyl Hydroxylase Domain Protein 3 Triggers Angiogenesis and Preserves Cardiac Function by Stabilizing Hypoxia Inducible Factor 1 Alpha Following Myocardial Infarction
Current Pharmaceutical Design Lipid Raft in Cardiac Health and Disease
Current Cardiology Reviews Coated with Nanomaterials Intraocular Lenses, Ophthalmic and Human Body Implantable Devices with High Catalytic Antioxidant Activities: A New Nanotechnology Strategy of Peroxidase Cellular Enzyme Mimics Increasing the Biocompatibility and Therapeutic Deployment of the Medical Prosthetic Device
Recent Patents on Drug Delivery & Formulation Nanotechnological Strategies for the Treatment of Neglected Diseases
Current Pharmaceutical Design Fabry Disease Cardiomyopathy: from Genes to Clinical Manifestations
Current Pharmaceutical Biotechnology Hydrogen Peroxide Produced by Mitochondrial Monoamine Oxidase Catalysis: Biological Implications
Current Pharmaceutical Design